Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling.
Hu B, Sun X, Yang Y, Ying Z, Meng J, Zhou C, Jiang G, Li S, Wu F, Zhao X, Zhu H, Wu H, Cai X, Shi Z, Yan S.
Hu B, et al. Among authors: zhou c.
FASEB J. 2019 Feb;33(2):2574-2586. doi: 10.1096/fj.201800920R. Epub 2018 Oct 4.
FASEB J. 2019.
PMID: 30285579
At the molecular level, tomatidine abrogated phosphorylation of c-Jun N-terminal kinase (JNK)/p38, NF-kappaB, and protein kinase B (Akt) pathway proteins by suppressing RANK expression, inhibiting the binding of TRAF6 to RANK, and downregulating the osteoclastogenesis mark …
At the molecular level, tomatidine abrogated phosphorylation of c-Jun N-terminal kinase (JNK)/p38, NF-kappaB, and protein kinase B (A …